GlassScriptPhysician profile
Johnny Altawil
NPI 1841439270
$7,267.31
in general payments reported to CMS, 2019-2025
23 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $284 · 2021: $745 · 2022: $759 · 2023: $3,636 · 2024: $683 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,050 · Food and Beverage: $1,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,050.00 |
| Food and Beverage | $1,709.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $3,313.48 | 2019-2025 | Rebyota |
| Abbvie INC. | $1,986.35 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $514.14 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $349.85 | 2019-2022 | |
| Pfizer INC. | $199.09 | 2019-2024 | |
| Celgene Corporation | $139.67 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $88.67 | 2021-2023 | |
| Braintree Laboratories, INC. | $85.67 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $84.21 | 2019-2023 | Dificid |
| Gilead Sciences, INC. | $84.20 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $80.51 | 2019-2024 | |
| Evoke Pharma, INC. | $64.97 | 2022-2023 | Gimoti |
| Daiichi Sankyo INC. | $61.70 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $39.71 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $33.14 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $27.28 | 2025 | Bylvay |
| Janssen Biotech, INC. | $24.84 | 2021 | |
| Ucb, INC. | $22.23 | 2019 | |
| Novo Nordisk INC | $21.30 | 2025 | Wegovy |
| Amag Pharmaceuticals, INC. | $16.41 | 2021 | |
| Redhill Biopharma INC. | $14.96 | 2021 | |
| Amgen INC. | $14.93 | 2023 | Amjevita, Avsola |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Altawil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.